Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Can This Tiny Biotech Take Down Amgen?

TheMotleyFool

0 0

Can This Tiny Biotech Take Down Amgen?Photo, wide shot, wide-angle lens, Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png

The biotech version of David vs. Goliath just got more interesting, with the $3.7-billion-market-cap Mirati Therapeutics (NASDAQ: MRTX) posting data this week for its KRAS inhibitor MRTX849 suggesting it can be competitive with AMG 510 from Amgen (NASDAQ: AMGN), which weighs in at a market cap of $126 million.

You can't make firm predictions on drugs from two different uncontrolled clinical trials, especially with low numbers of patients, but qualitatively, MRTX849 looks like it can stack up against AMG 510.

Here's how Mirati's data presented this week at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics stacks up against Amgen's data from the European Society for Medical Oncology late last month.

Source Fool.com

Like: 0

AMGN

Share